)
Visual
test
Gyre Therapeutics
Gyre Therapeutics (GYRE) investor relations material
Gyre Therapeutics Q4 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q4 2025 earnings summary12 Mar, 2026
Executive summary
Full-year 2025 revenue rose 10% year-over-year to $116.6 million, within revised guidance.
2026 revenue guidance set at $100.5–$111.0 million, reflecting a transition year with regulatory focus.
Agreement to acquire Cullgen for $300 million to expand into targeted protein degradation; closing expected Q2 2026.
Completed enrollment in 52-week Phase 3 pirfenidone trial for pneumoconiosis; NDA for Hydronidone in China planned for H1 2026.
U.S. IND application for Hydronidone in MASH-associated liver fibrosis anticipated in 2026.
Financial highlights
Q4 2025 revenue was $37.2 million, up 33.3% year-over-year, driven by new product launches and increased ETUARYⓇ sales.
Full-year 2025 revenue reached $116.6 million, up 10.2% from 2024, with growth from ContivaⓇ and EtorelⓇ launches.
Q4 2025 net loss was $1.4 million versus $0.6 million net income in Q4 2024; full-year 2025 net income was $9.9 million, down from $17.9 million in 2024.
Non-GAAP adjusted net income for 2025 was $18.9 million, up from $16.9 million in 2024.
Cash, cash equivalents, and deposits totaled $75.9 million as of December 31, 2025.
Outlook and guidance
2026 revenue expected to decline 4.8%–13.8% year-over-year, reflecting a transition period prioritizing regulatory activities.
Promotional activities for ContivaⓇ and EtorelⓇ to be moderated due to market uncertainties.
Guidance assumes constant FX rates and no major economic disruptions.
Partial view of Summaries dataset, powered by Quartr API
AI can get things wrong. Verify important information.Research faster. Power your platform.
Latest events from Gyre Therapeutics
- Merger creates a global leader in fibrosis, pain, and cancer with advanced degrader technologies.GYRE
Investor presentation12 Mar 2026 - F351 pivotal trial results expected in early 2025, driving global expansion and pipeline growth.GYRESidoti Micro-Cap Virtual Conference2 Feb 2026
- Phase III results for F351 in HBV fibrosis expected early 2025, with global expansion planned.GYREH.C. Wainwright 26th Annual Global Investment Conference 202421 Jan 2026
- Hydronidone advances in late-stage trials, showing strong efficacy and safety for liver fibrosis.GYREH.C. Wainwright 8th Annual MASH Virtual Conference19 Jan 2026
- Biotech aims to raise $150M for R&D and growth, facing China regulatory and audit risks.GYRERegistration Filing16 Dec 2025
- Annual meeting to vote on directors, executive pay, and auditor, with strong governance in place.GYREProxy Filing2 Dec 2025
- Virtual annual meeting to elect directors, approve pay, and ratify auditor on June 4, 2025.GYREProxy Filing2 Dec 2025
- Q3 2025 revenue up 20% to $30.6M, net income doubled, but full-year guidance was cut.GYREQ3 20257 Nov 2025
- Q2 2024 net income rose 20% to $4.5M on $25.2M revenue, with strong margins and pipeline progress.GYREQ2 202423 Oct 2025
Next Gyre Therapeutics earnings date
Q1 20268 May, 2026
Gyre Therapeutics
Next Gyre Therapeutics earnings date
Q1 20268 May, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Explore our global coverage